MedPath

LIVZON PHARMA

🇨🇳China
Ownership
-
Established
1985-01-26
Employees
8.9K
Market Cap
-
Website
http://www.livzon.com.cn
Introduction

The company was founded in January 1985. It is a comprehensive pharmaceutical group company integrating R&D, production and sales of pharmaceutical products, and is an A+H listed company. The company regards R&D innovation as the cornerstone of sustainable development, and continues to pay attention to new molecules and cutting-edge technologies in the global field of new drug research and development. Based on clinical value, differentiated forward-looking layout of innovative drugs and complex formulations with high barriers, the company focuses on the digestive tract, assisted reproduction, psychiatry, tumor immunity, etc., and has formed a complete product cluster and a differentiated product pipeline covering the entire R&D cycle. The company's main business is R&D, production and sales of pharmaceutical products. The main products include iLianan, Rivolol series products, Rebelix, Vitrex, Beiyi, Lisenbao, Lebald, Lifecon, Ripple, Conertin, Shenqi Fuzheng injection, antiviral granules, etc.; mirvastatin, acarbose, colistin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, mirbetaxim and ceftriaxone sodium, etc.; Mycoplasma pneumoniae IgM antibody detection reagents, antibody test reagents for human immunodeficiency Diagnostic reagent products such as kits and antinuclear antibody test kits. Corporate honors: Pearl Delle won the first Grand Prize for Outstanding Contribution to Science and Technology Progress in Zhuhai; Pearl Dole won the Grand Prize for Outstanding Contribution to Promoting Scientific and Technological Progress in Zhuhai; Jinqi Fuzheng Injection won the first prize of the 2006 China Society of Integrative Traditional Chinese and Western Medicine Science and Technology Award, etc.

A Study to Evaluate the Efficacy and Safety of LZM012

Phase 3
Recruiting
Conditions
Psoriasis
Interventions
Biological: LZM012
Biological: Secukinumab
First Posted Date
2023-11-01
Last Posted Date
2023-11-01
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
918
Registration Number
NCT06110676
Locations
🇨🇳

Huashan Hospital, Shanghai, Shanghai, China

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Phase 3
Completed
Conditions
Stress Ulcer Bleeding
Interventions
First Posted Date
2023-05-03
Last Posted Date
2023-05-03
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
449
Registration Number
NCT05841394
Locations
🇨🇳

Shanghai Jiaotong University Affiliate Ruijin Hospital, Shanghai, Shanghai, China

🇨🇳

The First Affiliated Hopspital of Xinjiang Medical University, Urumchi, Xinjiang, China

A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5

Early Phase 1
Active, not recruiting
Conditions
COVID-19 Pandemic
Interventions
Biological: V-01
Biological: V-01-351/V-01-B5
Biological: V-01/V-01-B5
First Posted Date
2022-10-19
Last Posted Date
2022-11-07
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
48
Registration Number
NCT05585567
Locations
🇨🇳

Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

Early Phase 1
Active, not recruiting
Conditions
COVID-19 Pandemic
Interventions
Biological: V-01D-351
Biological: CoronaVac
First Posted Date
2022-10-17
Last Posted Date
2022-10-19
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
40
Registration Number
NCT05583357
Locations
🇨🇳

Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

Phase 2
Conditions
COVID-19 Pandemic
Interventions
Biological: Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine
First Posted Date
2022-03-10
Last Posted Date
2022-03-10
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
20
Registration Number
NCT05273528
Locations
🇨🇳

Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

Phase 2
Conditions
COVID-19 Pandemic
Interventions
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine
First Posted Date
2022-02-15
Last Posted Date
2022-03-03
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
34
Registration Number
NCT05239832
Locations
🇨🇳

The Fifth Peoples' Hospital of Zhuhai, Zhuhai, Guangdong, China

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

Phase 2
Conditions
COVID-19 Pandemic
Interventions
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
Biological: SARS-Cov-2 Vaccine Inactivated
First Posted Date
2022-02-14
Last Posted Date
2022-03-29
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
150
Registration Number
NCT05238649
Locations
🇨🇳

Zhuhai Peoples' Hospital Medical Group, Zhuhai, Guangdong, China

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization

Not Applicable
Conditions
COVID-19 Pandemic
Interventions
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine
First Posted Date
2021-11-18
Last Posted Date
2021-11-18
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
45
Registration Number
NCT05125874
Locations
🇨🇳

Zhuhai Peoples' Hospital Medical Group, Zhuhai, Guangdong, China

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Phase 3
Active, not recruiting
Conditions
COVID-19 Pandemic
Interventions
Biological: Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
Other: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
First Posted Date
2021-10-27
Last Posted Date
2023-04-25
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
22500
Registration Number
NCT05096845
Locations
🇵🇭

Mary Mediatrix Medical Center, Lipa city, Batangas, Philippines

🇷🇺

Central Clinical Hospital of the Russian Academy of Sciences, Engels, Russian Federation

🇵🇭

Makati Medical Center, Makati City, Philippines

and more 22 locations

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

Phase 3
Completed
Conditions
COVID-19 Pandemic
Interventions
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
Biological: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
First Posted Date
2021-10-27
Last Posted Date
2023-04-25
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
10381
Registration Number
NCT05096832
Locations
🇲🇾

Sarawak General Hospital, Kuching, Sarawak, Malaysia

🇲🇾

Sunway Medical Centre (SunMed), Petaling Jaya, Malaysia

🇲🇾

Seri Manjung Hospital, Seri Manjung, Malaysia

and more 15 locations
© Copyright 2025. All Rights Reserved by MedPath